Conduit Pharmaceuticals Stock (NASDAQ: CDT)

Conduit Pharmaceuticals (NASDAQ:CDT) Stock, Quote.Headers.trade-ideas

Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Perché queste 3 azioni possono essere una miniera d’oro

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

DATS

IGMS

VMAR

XTIA

XXII

Nasdaq Down Over 2%; Walgreens Posts Upbeat Results

jobs ai2

Earnings

Dow Dips 500 Points; US Economy Adds 256,000 Jobs In December

Amazon, Crowdstrike, Autodesk, Dell, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

AMPG

AREB

BHAT

BWMN

CALM

DRIO

EONR

GRFX

HOTH

JBDI

LAES

RGTI

RIME

SANA

SLDB

SVMH

Why Cal-Maine Foods Shares Are Trading Higher By 4%; Here Are 20 Stocks Moving Premarket

Conduit Pharmaceuticals Inc. - Common Stock

Conduit Pharmaceuticals Inc

Infinitii Ai Inc

CDT Environmental Technology Investment Holdings Limited - ordinary shares

CDT Environmental Technology Investment Holdings Ltd

CDTI ADVANCED MATERIALS by CDTI Advanced Materials, Inc.

CDTi Advanced Materials Inc

Cidara Therapeutics Inc

JP Morgan analyst Jeremy Metz maintains First Quantum Minerals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FM#TSX">FM</a>) with a Neutral and raises the price target from C$17 to C$18.

Price Target

Analyst Ratings

TSX:FM

JP Morgan Maintains Neutral on First Quantum Minerals, Raises Price Target to C$18

RBC Capital analyst Drew McReynolds reiterates Cogeco Communications (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CCA#TSX">CCA</a>) with a Sector Perform and maintains C$77 price target.

Reiteration

TSX:CCA

RBC Capital Reiterates Sector Perform on Cogeco Communications, Maintains C$77 Price Target

Grab Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) shares are trading marginally higher <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">in the premarket session on Wednesday.</a>
The firm has announced a <a target="_blank" href="https://www.grab.com/sg/press/others/grab-and-byd-enter-strategic-partnership-to-expand-electric-vehicle-fleet-offering-across-southeast-asia/" rel="noreferrer noopener">regional partnership</a> with BYD to expand access to up to 50,000 electric vehicles for Grab&#8217;s driver-partners across Southeast Asia, enhancing the availability of green vehicles for its users.
This collaboration aims to overcome the region&#8217;s key barrier to EV adoption: high upfront costs.
This partnership spans six Southeast Asian countries—Indonesia, Malaysia, Philippines, Singapore, Thailand, and Vietnam—and includes models like the DENZA D9, BYD ATTO3, BYD SEAL, and BYD M6.
The DENZA D9, a luxury electric vehicle, will be featured in GrabExec, setting a new standard for executive transportation with its advanced features and sustainability.
Last July, BYD announced a multi-year strategic partnership to add 100,000 new BYD electric vehicles to the&nbsp;Uber platform <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/40077563/uber-and-byd-team-up-for-electric-future-100k-evs-to-hit-the-road" rel="noreferrer noopener">in key global markets.</a> However, the deal with Uber focused on Europe and Latin America, with plans to expand to the Middle East, Canada, Australia, and New Zealand.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42996752/us-stocks-to-open-higher-ahead-of-december-inflation-data-all-eyes-on-baking-earnings-by-jpm-goldman-citi-wells-fargo" rel="noreferrer noopener">US Stocks To Open Higher Ahead Of December Inflation Data: All Eyes On Banking Stocks As JPMorgan, Goldman, Citi, Wells Fargo Report Quarterly Earnings</a>
In the latest development with Grab, BYD plans to provide Grab&#8217;s fleet and driver-partners with access to affordable BYD vehicles, including extended warranties for the vehicles&#8217; batteries.
Drivers can choose to rent these EVs through Grab&#8217;s fleet partners or access financing options via Grab&#8217;s car ownership schemes. This partnership aligns with Grab&#8217;s sustainability goals, helping accelerate the transition to zero-emission transportation.
In countries like Singapore and Thailand, Grab users can select an &#8220;Eco-Friendly Ride&#8221; option at no extra charge, prioritizing green vehicles for their rides.
Liu Xueliang, General Manager of BYD Asia Pacific Auto Sales Division, said, &#8220;We are excited to partner with Grab as the leading on-demand transport provider in Southeast Asia and push forward the transition to electric vehicles in the region.&#8221;
Per a <a target="_blank" href="https://www.statista.com/outlook/mmo/electric-vehicles/southeast-asia" rel="noreferrer noopener">report</a> by Statista, the Electric Vehicles market in Southeast Asia is expected to reach $6.798 billion by 2025. From 2025 to 2029, the market is projected to grow at a rate of 4.02% annually. By 2029, the market volume is expected to hit $7.958 billion.
The partnership will also focus on deep technological integration to enhance Grab&#8217;s services. BYD vehicles will integrate with Grab&#8217;s platform through IoT, providing real-time data on driving patterns and behaviors. This data will help improve driver safety and overall experience, with features like larger screens displaying jobs, navigation, and chats directly in the vehicle&#8217;s head unit.
The integration of real-time data, such as weather and traffic conditions, will also help improve ride reliability and route optimization, ensuring better ETA accuracy and efficient navigation.
Price Action: GRAB shares are trading higher by 2.06% to $4.45 premarket at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/01/42967576/meta-investors-push-mark-zuckerberg-to-replace-72b-cash-with-bitcoin-to-combat-inflation-heres-what-it-means-for-investors" target="_blank" rel="noreferrer noopener">Meta Investors Push Mark Zuckerberg To Replace $72B Cash With Bitcoin To Combat Inflation: Here&#8217;s What It Means For Investors</a></li>
</ul>
Photo via Shutterstock.

Movers

General

BYDDY

GRAB

Grab Teams Up With BYD To Boost EV Availability For Southeast Asia's Driver-Partners

- Presentation&nbsp;
&nbsp;
<figure class="image"><img src="https://www.sec.gov/Archives/edgar/data/1803901/000095017025005641/talk-ex99_1s19.jpg" alt="Slide 19" /></figure>

Guidance

TALK

Talkspace Sees 2024 Revenue Guidance Of ~$185M-$195M, Up 23%-30% YoY; 3-Year Revenue CAGR Outlook Of 20%-25%

VCIG

VCI Global Announces Exclusive Distributorship Of Secure Encryption Storage Limited For Data Security Solutions In Malaysia

WIIM

CVGW

Calavo Growers shares are trading lower after the company reported worse-than-expected Q4 adjusted EPS results.

PRTH

Priority Technology shares are trading lower after the company announced a share offering of 9,157,600 shares.

CEO Marc Rowan to Enter Into 5-Year Employment Agreement Extension
Jim Zelter Named President of Apollo Global Management
John Zito Named Co-President of Apollo Asset Management Alongside Scott Kleinman
NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Apollo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) today announced that Jim Zelter has been named President of Apollo Global Management, Inc. (AGM), the holding company for its asset management and retirement services businesses. The newly created role reflects Apollo's continued operational expansion and its significant growth plans across both the Apollo Asset Management, Inc. (AAM) and Athene Holding Ltd. subsidiaries. As President, Zelter will work closely with AGM CEO Marc Rowan to drive Apollo's recently announced five-year plan and lead a number of key strategic initiatives across its asset management and retirement services businesses.

Management

Apollo Announces Jim Zelter As President Of Apollo Global Management; John Zito Named Co-President Of Apollo Asset Management With Scott Kleinman; CEO Marc Rowan Signs 5-Year Agreement Extension

TOMZ

TOMI Environmental Solutions Regains Compliance With Nasdaq Requirements

GNLN

Greenlane Regains Full Compliance With Nasdaq Continued Listing Rules
ACCESSWIRE

KROS

Keros Therapeutics shares are trading lower after the company announced an update on its Phase 2 TROPOS trial and halted all dosing based on the ongoing safety review.

JP Morgan analyst Tami Zakaria maintains Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) with a Neutral and raises the price target from $450 to $470.

JP Morgan Maintains Neutral on Deere, Raises Price Target to $470

QUBT

Quantum Computing Collaborates With Sanders Tri-Institutional Therapeutics Discovery Institute To Support Research Using Dirac-3 Systems

BECN

QXO Proposes To Acquire Beacon Roofing Supply For $124.25/Share In Cash, Implying Total Transaction Valued Of ~$11B

Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the company's FDA-approved, NGS-based in vitro diagnostic device, xT CDx. Beginning today, xT CDx is now available for all ordering clinicians nationwide. xT CDx is a FDA-approved test that delivers comprehensive insights with one of the largest reported gene panels available.
xT CDx is a 648-gene next-generation sequencing test for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients. xT CDx leverages a normal-matched approach, which is a method of parallel DNA sequencing of a solid tumor and normal patient sample that can lead to more accurate identification of cancer-driving somatic variants. All orders for tumor + normal match tests – traditionally run on the company's signature xT assay – will now be run as xT CDx with no changes to the current ordering workflow.

Biotech

Tempus Announces The Launch Of FDA-Approved xT CDx Test, Now Available For All Ordering Clinicians Nationwide

MYGN

Myriad Genetics Sees FY25 Adj. EPS $0.07-$0.11 Vs $0.08 Est.; Revenue $840M-$860M Vs $876.702M Est.

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>)&nbsp;a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB008, for treatment in H5N1, commonly known as "Bird Flu." The Company is currently approaching potential university partners to expedite the preclinical work required for a Phase I study.
H5N1 is a viral infection often contracted by contact with sick birds, yet it can also be passed from person to person. Symptoms begin within two to eight days and can seem like the common flu, causing cough, fever, sore throat, muscle aches, headache, and shortness of breath. The disease can carry a high mortality in humans. Some antiviral drugs, if taken within two days of symptoms, may help. Last week, the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4340843-1&amp;h=149896997&amp;u=https%3A%2F%2Fldh.la.gov%2Fnews%2FH5N1-death&amp;a=Louisiana+Department+of+Health+recently+reported+the+first+U.S.+death+from+H5N1">Louisiana Department of Health recently reported the first U.S. death from H5N1</a>.

TCBP

TCBP Announces That It Intends To Begin Proof Of Concept Preclinical Studies For Its Lead Therapeutic TCB008, For Treatment In H5N1, Commonly Known As "Bird Flu"

Myriad Genetics Sees Prelim. Q4 Adj. EPS $0.03-$0.04 Vs $0.03 Est.; Revenue $209M-$211M Vs $212.873M Est.

JP Morgan analyst Tami Zakaria maintains CNH Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) with a Neutral and raises the price target from $12 to $13.

JP Morgan Maintains Neutral on CNH Industrial, Raises Price Target to $13

UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) is gearing up to release its<a href="https://www.benzinga.com/quote/UNH/earnings"> fourth quarter earnings report</a>, and investors are watching closely. Stephanie Link, CIO at Hightower Advisors LLC, has dubbed the managed care giant the &#8220;number one company on sale&#8221; despite potential near-term earnings pressure.
<h2 class="wp-block-heading">&#8216;They&#8217;re Probably Gonna Miss&#8217; Q4 Earnings Expectations </h2>
With estimated earnings per share (EPS) of $6.73 and revenue projections around $101.75 billion according to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1">Benzinga Pro</a> data, UnitedHealth faces scrutiny over high utilization rates that could dent its profit margins. 
On earnings, &#8220;they're probably gonna miss&#8230;because utilization rates are so strong, so high, and it hurts their cost,&#8221; Link <a href="https://www.cnbc.com/video/2025/01/14/trade-tracker-stephanie-link-buys-unitedhealth.html">remarked</a> during CNBC's Halftime Report. 
However, she sees this as a temporary hiccup, not a long-term trend.
Read Also: <a href="https://www.benzinga.com/general/health-care/24/12/42744629/unitedhealth-group-ceo-reportedly-says-company-will-hit-financial-records-execs-murder-public-outcry-are-backdrop-for-q4-earnings">UnitedHealth Group CEO Reportedly Says Company Will Hit Financial Records: Exec&#8217;s Murder, Public Outcry Are Backdrop For Q4 Earnings</a>
<h2 class="wp-block-heading">From Beat-And-Raise To Strategic Patience</h2>
UnitedHealth, long celebrated for its consistent earnings beats, hasn't seen much stock movement in the past year, but that hasn&#8217;t dampened Link&#8217;s enthusiasm. &#8220;They have a gem with Optum,&#8221; she said, referring to the segment responsible for 24% of the company's revenue and 12% of operating profits. 
Ongoing M&amp;A activity is bolstering Optum's growth trajectory, even as the broader healthcare sector struggles to find favor with investors.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073053/Screenshot-2025-01-15-at-6.00.36-PM.png" alt="" class="wp-image-734548" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073053/Screenshot-2025-01-15-at-6.00.36-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073053/Screenshot-2025-01-15-at-6.00.36-PM-300x233.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Technically, UnitedHealth shares are experiencing bullish buying pressure, with the stock trading above its eight, 20 and 200-day simple moving averages (SMAs).
At $543.74 per share, the price positions UNH stock as a bullish signal across these metrics, although its moving average convergence/divergence (MACD) indicator of a negative 6.15 suggests caution. Meanwhile, UNH stock&#8217;s relative strength index (RSI) of 56.86 signals moderate strength but room for additional upward movement.
<h2 class="wp-block-heading">A Buying Opportunity In The Making?</h2>
Historically trading at a premium valuation, UnitedHealth now sits at 17 times earnings, compared to its typical 21 times multiple. &#8220;When I owned it, it was trading at something like 25 times, and every quarter was a beat and raise,&#8221; Link noted. Despite the temporary pressure, she believes the stock&#8217;s visibility will only improve post-earnings.
Link remains bullish on UnitedHealth&#8217;s potential, citing strong fundamentals, a promising $18 billion buyback program and expectations of double-digit earnings and revenue growth ahead. &#8220;We&#8217;re gonna see double-digit growth in earnings and revenues,&#8221; she emphasized, viewing current regulatory and litigation concerns as mere &#8220;noise.&#8221;
UnitedHealth's premium status as the &#8220;number one managed care company&#8221; may make today&#8217;s market lull a golden opportunity for savvy investors.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/insights/news/25/01/42776487/heres-how-much-you-would-have-made-owning-unitedhealth-group-stock-in-the-last-10-years">Here&#8217;s How Much You Would Have Made Owning UnitedHealth Group Stock In The Last 10 Years</a></li>
</ul>
Photo: Shutterstock

Health Care

Technicals

Previews

UnitedHealth: The 'Number One Company On Sale' Ahead Of Q4 Earnings Report

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Conduit Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) stock is up on Wednesday following a shareholder update concerning a major investor in the company.



New filings with the Securities and Exchange Commission (SEC) reveal that Nirland Limited <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318518480&amp;type=PDF&amp;symbol=CDT&amp;cdn=ab0223c3ed6ed1bb801100f67e0b2323&amp;companyName=Conduit+Pharmaceuticals+Inc.&amp;formType=SC+13G%2FA&amp;formDescription=%5BAmend%5D+Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-08-13">holds a 14.8% stake in CDT stock</a>. This comes from the 12.5 million shares off CDT that the company owns, as well as warrants for another 2 million shares.



Nirland Limited&rsquo;s stake in Conduit Pharmaceuticals is based on the company&rsquo;s outstanding shares of CDT stock. That was sitting at 98,004,699 shares at the time of this writing.



Nirland Limited&rsquo;s stake in Conduit Pharmaceuticals comes from a Senior Secured Promissory Note issued earlier this month. This was part of Conduit Pharmaceuticals&rsquo; merger agreement with Murphy Canyon Acquisition Corp.



<h2>CDT Stock Movement on Wednesday</h2>



Following this news, shares of CDT stock are seeing heavy trading today. This has more than 72 million units changing hands as of this writing. That&rsquo;s a massive increase compared to the company&rsquo;s daily average trading volume of about 10 million shares.



CDT stock is up 11.7% as of Wednesday morning. Even so, the clinical-stage specialty biopharmaceutical company&rsquo;s shares are still down 96.7% since the start of the year.



Investors will want to stick around for even more of the most recent stock market stories on Wednesday!



We have all of the hottest stock market news ready to go today! Among that is what has shares of Intuitive Machines&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/lunr-stock-quote/">LUNR</a>), Nuburu&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/buru-stock-quote/">BURU</a>) and Clover Health&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/clov-stock-quote/">CLOV</a>) stock on the move today. You can catch up on all of this at the links below!



<h2>More Stock Market News for Wednesday</h2>



<ul><li><a href="https://investorplace.com/2024/08/trade-of-the-day-explore-the-final-frontier-with-intuitive-machines-lunr-stock/">Trade of the Day: Explore the Final Frontier with Intuitive Machines (LUNR) Stock</a></li>



<li><a href="https://investorplace.com/2024/08/why-is-nuburu-buru-stock-up-47-today/">Why Is Nuburu (BURU) Stock Up 47% Today?</a></li>



<li><a href="https://investorplace.com/2024/08/clov-stock-alert-what-to-know-about-clover-healths-big-insider-buy/">CLOV Stock Alert: What to Know About Clover Health&rsquo;s Big Insider Buy</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/why-is-conduit-pharmaceuticals-cdt-stock-up-12-today/">Why Is Conduit Pharmaceuticals (CDT) Stock Up 12% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Conduit Pharmaceuticals (CDT) Stock Up 12% Today?

06:14 EDT Conduit Pharmaceuticals (CDT) files $100M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mo...

Conduit Pharmaceuticals files $100M mixed securities shelf

Conduit Pharmaceuticals ( ($CDT) ) has issued an update. Conduit Pharmaceuticals Inc. recently entered into financial agreements to secure funding,...

Conduit Pharmaceuticals Secures Funding and Modifies Debt Agreements

Conduit Pharmaceuticals announces debt restructuring and additional notes

The latest announcement is out from Conduit Pharmaceuticals ( ($CDT) ). Conduit Pharmaceuticals Inc. has appointed Simon Fry as a director, leverag...

Conduit Pharmaceuticals Announces Leadership Changes and Bylaws Update

Conduit Pharmaceuticals (CDT) announced that the Japan Patent Office, JPO, has granted approval of a composition of matter patent application for t...

Conduit Pharmaceuticals receives further patent approval for AZD1656

The company is not selling any securities under this prospectus and will not receive any proceeds from the sale of its common stock by the selling ...

Conduit Pharmaceuticals files to sell 75M shares of common stock for holders

Conduit Pharmaceuticals (CDT) announced that it has entered into an agreement with SARBOR to leverage an advanced artificial intelligence and cyber...

Conduit Pharmaceuticals to enter agreement with SARBOR

Conduit Pharmaceuticals ( ($CDT) ) just unveiled an announcement. Conduit Pharmaceuticals has entered into a strategic agreement with SARBORG Limit...

Conduit Pharmaceuticals Leverages AI for Drug Development

Conduit Pharmaceuticals ( ($CDT) ) has issued an announcement. Conduit Pharmaceuticals Inc. has been notified by Nasdaq of its non-compliance with ...

Conduit Pharmaceuticals Faces Nasdaq Delisting, Plans Stock Split

Press Releases

Conduit Pharmaceuticals to Join Russell 3000® Index

Legal

Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Contracts

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline

Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders

Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics

Comments

Conduit Pharmaceuticals

Conduit Pharmaceuticals (CDT) Forecast

Conduit Pharmaceuticals (NASDAQ:CDT) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga